TY - JOUR
T1 - Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas
AU - Alentorn, Agustì
AU - Dehais, Caroline
AU - Ducray, Fraņois
AU - Carpentier, Catherine
AU - Mokhtari, Karima
AU - Figarella-Branger, Dominique
AU - Chinot, Olivier
AU - Cohen-Moyal, Elisabeth
AU - Ramirez, Carole
AU - Loiseau, Hugues
AU - Elouahdani-Hamdi, Selma
AU - Beauchesne, Patrick
AU - Langlois, Olivier
AU - Desenclos, Christine
AU - Guillamo, Jean Sébastien
AU - Dam-Hieu, Phong
AU - Ghiringhelli, Fraņois
AU - Colin, Philippe
AU - Godard, Joel
AU - Parker, Fabrice
AU - Dhermain, Frédéric
AU - Carpentier, Antoine F.
AU - Frenel, Jean Sebastien
AU - Menei, Philippe
AU - Bauchet, Luc
AU - Faillot, Thierry
AU - Fesneau, Mélanie
AU - Fontaine, Denys
AU - Motuo-Fotso, Marie Jeannette
AU - Vauleon, Elodie
AU - Gaultier, Claude
AU - Le Guerinel, Caroline
AU - Gueye, Edouard Marcel
AU - Noel, Georges
AU - Desse, Nicolas
AU - Durando, Xavier
AU - Barrascout, Eduardo
AU - Wager, Michel
AU - Ricard, Damien
AU - Carpiuc, Ioana
AU - Delattre, Jean Yves
AU - Idbaih, Ahmed
N1 - Publisher Copyright:
© 2015 American Academy of Neurology.
PY - 2015/10/13
Y1 - 2015/10/13
N2 - Objectives: We aimed to study the potential clinical relevance of 9p allelic loss, with or without copy number variation, in 1p/19q codeleted anaplastic oligodendroglial tumors (AOTs). Methods: This study enrolled 216 patients with 1p/19q codeleted AOT. The prognostic value of 9p allelic loss was investigated using a French nation-wide prospective registry, POLA (prise en charge des tumeurs oligodendrogliales anaplasiques) and high-density single nucleotide polymorphism arrays. We validated our results using the Repository of Molecular Brain Neoplasia Data (REMBRANDT) dataset. Results: The minimal common region of allelic loss in chromosome arm 9p was 9p21.3. Allelic loss of 9p21.3, detected in 41.7% of tumors, was associated with shorter progression-free and overall survival rates in univariate (p 5 0.008 and p , 0.001, respectively) and multivariate analyses (p 5 0.009 and p 5 0.009, respectively). This finding was validated in the REMBRANDT dataset in univariate and multivariate analysis (p 5 0.01 and p 5 0.01, respectively). Conclusion: Our study highlights a novel potential prognostic biomarker in 1p/19q codeleted AOT. Further prospective studies are warranted to investigate our finding.
AB - Objectives: We aimed to study the potential clinical relevance of 9p allelic loss, with or without copy number variation, in 1p/19q codeleted anaplastic oligodendroglial tumors (AOTs). Methods: This study enrolled 216 patients with 1p/19q codeleted AOT. The prognostic value of 9p allelic loss was investigated using a French nation-wide prospective registry, POLA (prise en charge des tumeurs oligodendrogliales anaplasiques) and high-density single nucleotide polymorphism arrays. We validated our results using the Repository of Molecular Brain Neoplasia Data (REMBRANDT) dataset. Results: The minimal common region of allelic loss in chromosome arm 9p was 9p21.3. Allelic loss of 9p21.3, detected in 41.7% of tumors, was associated with shorter progression-free and overall survival rates in univariate (p 5 0.008 and p , 0.001, respectively) and multivariate analyses (p 5 0.009 and p 5 0.009, respectively). This finding was validated in the REMBRANDT dataset in univariate and multivariate analysis (p 5 0.01 and p 5 0.01, respectively). Conclusion: Our study highlights a novel potential prognostic biomarker in 1p/19q codeleted AOT. Further prospective studies are warranted to investigate our finding.
UR - http://www.scopus.com/inward/record.url?scp=84944392284&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000002014
DO - 10.1212/WNL.0000000000002014
M3 - Article
C2 - 26385879
AN - SCOPUS:84944392284
SN - 0028-3878
VL - 85
SP - 1325
EP - 1331
JO - Neurology
JF - Neurology
IS - 15
ER -